IFW



Patent Application Attorney Docket No. PC23214A

eb triffy that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 1st day of September 2004.

(Signature of person mailing Heather Randhahn

(Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ralph H. Lambalot

APPLICATION NO.: 10/763,860 : Examiner: To be assigned

FILING DATE: January 23, 2004 : Group Art Unit: 1645

TITLE: NOVEL METHODS INVOLVING THE DETERMINATION OF ACTIVITY OF ENZYMES THAT USE OR PRODUCE PROSTAGLANDIN ENDOPEROXIDE H2

Hon. Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Alexandria, VA 22313-1430

Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed. The references were listed in the European Search Report (copy enclosed) for the corresponding EP application.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: 9/1/01

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(617) 551-3223

Respectfully submitted,

Nicholas I. Slepchuk, Jr. Attorney for Applicant(s)

Reg. No. 32,174

NEGRMATION DISCLOSURE CITATION						TY. DOC	KET NO	D. PC232	14A S	ERIAL NO	. 10/76	3,860		
(Use	several sh	eets if	necess	ary)	AP	PLICAN <sup>®</sup>	T Ral	ph H. Lar	nbalot			••		
						ING DA	TE Janu	uary 23, 2004 GR		ROUP 1645				
					U.S	. PATEN	IT DOC	UMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	DATE	
	2002	0	2	2	2	4	4 A1	2/21/02	Kim et al.					
	2002	0	7	2	1	2	5 A1	6/13/02	Morelle et al.					
	2003	6 3	1	5 5	7 5	0	84 A1 2 B1	8/21/03 5/28/02	Jakobsson et al.					
	6								Jakobsson et al.					
					FORE	GN PAT	ENT DO	CUMEN	TS	- γ		·		
	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSI		
												YES	NO	
•		ОТН	ER DO	CUMEN	ITS (Inc	cluding A	Author, 7	itle, Date	Pertinent Page	s, Etc.)	<u> </u>	1		
	Janero	o, D.R., (	1990) <i>Fr</i> e	e Radica	l Biol. Me	ed. 9:515-5	i40							
	Hamberg, M. and Samuelson, B. (1974) <i>Proc. Natl. Acad. U.S.A.</i> 71:3400-3404													
	Hammarstrom, S. (1982) Arch. Biochem. Biophys. 214:431-445													
	Ishii, F	phage-lik	ke cell line	, RAW 2	64.7, by	n and indu Mallotus ja 102, pages	ponicus pl	ostaglandin nloroglucino	endoperoxide synth I derivatives", BBA-0	ase-2 is inhib General Subje	ited in a mur ects, Elsevier	ine Scient	ce	
	Publis			lik. W. (1	986) <i>Dige</i>	stive Dise	ases and	Sciences 31	:6S-19S					
	Publis	ek, S.J.,	and Paw	,										
	Publis: Kontur				.W. (199	5), J. Enzy	me Inhib.	9:253-261.						
	Publis.  Kontur  Lederg	gerber, D		tmann, F			rme Inhib.	9:253-261.				·-		
	Publis.  Kontur  Lederg	gerber, D	). and Har	tmann, F			me Inhib.	9:253-261.						
XAMINER	Publis.  Kontur  Lederg	gerber, D	). and Har	tmann, F				9:253-261.	ED.					

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE